Michael Fall, DO
Pulmonary Disease · Denver, CONPI 1851548648
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $964 of the $1,543 with a category attached, or 62.4%. 8 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 52.6% of the total. Reporting peaked in 2019 at $817 and has fallen 68.4% since, to $259 in 2025.
Across 13 payments — averaging $118.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$812
- Inari Medical, Inc.$195
- Jazz Pharmaceuticals Inc.$135
- Insmed, Inc.$130
- Harmony Biosciences LLC$124
- Portola Pharmaceuticals, LLC$91
- plus $56 from 2 others
What the payments were for
- Travel & lodging$56136%
- Food & beverage$96462%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 4 | $812 |
| Inari Medical, Inc. | 1 | $195 |
| Jazz Pharmaceuticals Inc. | 1 | $135 |
| Insmed, Inc. | 2 | $130 |
| Harmony Biosciences LLC | 1 | $124 |
| Portola Pharmaceuticals, LLC | 1 | $91 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,543 in reported general payments places this provider in the 60th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $101,413 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $23,117 |
| Spiriva RespimatTiotropium Bromide | 32 | $21,057 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $14,368 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $11,782 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $10,844 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $10,842 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $9,713 |
| Spiriva HandihalerTiotropium Bromide | 16 | $8,117 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,767 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $2,641 |
| Montelukast Sodium | 95 | $605 |
| Modafinil | 11 | $450 |
| Dextroamphetamine Sulfate | 13 | $318 |
| Azithromycin | 25 | $225 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Barry MakeDenver$162K
- Amy OlsonDenver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.